HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

"Deceptive" weight-loss marketers pay up

This article was originally published in The Tan Sheet

Executive Summary

A federal district court orders Bronson Partners and its officer, Martin Howard, to pay the Federal Trade Commission nearly $2 million for making deceptive claims that its Chinese Diet Tea and Bio-Slim Patch products allow users to lose weight quickly without diet or exercise, FTC announces Jan. 11. Additionally, the U.S. District Court for the District of Connecticut granted the commission's request to prohibit the defendants from deceptively selling or advertising any weight-loss products, and ordered the firm to help FTC identify consumers who lost money on the products. Ads claimed the tea could "neutralize the absorption of fattening foods" and said "repulsive, excess ugly fatty tissue will disappear" by using the patch. The FTC filed its complaint against Bronson as part of its "Big Fat Lie" law enforcement sweep in 2004 (1"The Tan Sheet" Nov. 15, 2004)

You may also be interested in...



“Operation Big Fat Lie”: FTC Files Suits, Fights Bogus Weight-Loss Ads

FTC's "Red Flag" initiative has roughly halved the number of ads with fraudulent weight-loss claims since its inception, according to the commission

Biogen Sees Improving Momentum In Slow Leqembi Launch

Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS135312

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel